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Abstract
Background: Mucormycosis is a rare and potentially fatal fungal infection occurring primarily in severely
immunosuppressed patients. Because it is so rare, reports in the literature are mainly limited to case reports or small
case series. The aim of this study was to evaluate inpatient mortality, length of stay (LOS), and costs among a
matched sample of high-risk patients with and without mucormycosis in a large nationally representative database.
Methods: We conducted a retrospective analysis using the 2003–2010 Healthcare Cost and Utilization Project –
Nationwide Inpatient Sample (HCUP-NIS). The NIS is a nationally representative 20% sample of hospitalizations from
acute care United States (US) hospitals, with survey weights available to compute national estimates. We classified
hospitalizations into four mutually exclusive risk categories for mucormycosis: A- severely immunocompromised,
B- critically ill, C- mildly/moderately immunocompromised, D- major surgery or pneumonia. Mucormycosis hospitalizations
(“cases”) were identified by ICD-9-CM code 117.7. Non-mucormycosis hospitalizations (“non-cases”) were
propensity-score matched to cases 3:1. We examined demographics, clinical characteristics, and hospital
outcomes (mortality, LOS, costs). Weighted results were reported.
Results: From 319,366,817 total hospitalizations, 5,346 cases were matched to 15,999 non-cases. Cases and
non-cases did not differ significantly in age (49.6 vs. 49.7 years), female sex (40.5% vs. 41.0%), White race
(53.3% vs. 55.9%) or high-risk group (A-49.1% vs. 49.0%, B-20.0% vs. 21.8%, C-25.5% vs. 23.8%, D-5.5% vs. 5.4%).
Cases experienced significantly higher mortality (22.1% vs. 4.4%, P < 0.001), with mean LOS and total costs
more than 3-fold higher (24.5 vs. 8.0 days and $90,272 vs. $25,746; both P < 0.001).
Conclusions: In a national hospital database, hospitalizations with mucormycosis had significantly higher
inpatient mortality, LOS, and hospital costs than matched hospitalizations without mucormycosis. Findings
suggest that interventions to prevent or more effectively treat mucormycosis are needed.
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Background
Mucormycosis (formerly zygomycosis) is a rare invasive
fungal infection (IFI) associated with substantial morbid-
ity and mortality. Immunosuppression is a common pre-
disposing factor for mucormycosis, with the infection
generally limited to patients with hematological malig-
nancies or hematopoietic stem cell transplants, solid-
organ transplants, and diabetes [1-5]. A review of 929
mucormycosis cases reported since 1940 found the most
common underlying conditions/risk factors to be diabetes
(36%), malignancies (17%), and organ transplant (bone
marrow or solid organ; 12%) [5]. Between 2001 and 2005,
analyses of data from the Transplant Associated Infections
Surveillance Network (TRANSNET), showed that mucor-
mycosis represented 8% and 2% of IFIs found in pa-
tients receiving hematopoietic stem cell and solid organ
transplant recipients, respectively [6,7]. More recent pub-
lications from Europe and Asia highlight the increasing
recognition of mucormycosis around the globe, and also
present data supporting a shift from such traditional risk
factors, with hematological malignancies as the most com-
mon underlying condition [8-10].
With advances in treatment, mortality rates among pa-
tients infected with mucormycosis have declined [3], but
recent estimates of 90-day mortality continue to range
from 20% to 58% [1-3,11,12]. Hospitalizations for mucor-
mycosis are also associated with prolonged hospital length
of stay, substantial use of intensive care services, and ex-
cess costs of over $30,000 [13-15].
To date, mucormycosis has been studied in small and
narrowly defined populations or as a subgroup within a
larger sample of patients with IFIs, resulting in sample
sizes of 200 cases or fewer [2-4,11-13,15]. Such studies
have limited utility in understanding the true clinical and
economic burden of this condition. To address these gaps,
we evaluated the epidemiology, inpatient mortality, hos-
pital days, and hospitalization costs among a large sample
of hospitalized patients with mucormycosis using a United
States (US) nationally representative inpatient dataset.
Methods
Data source
We conducted a cost-of-illness analysis of hospital discharge
data from the Healthcare Cost and Utilization Project—
Nationwide Inpatient Sample (HCUP-NIS) from 2003
through 2010. The HCUP-NIS, maintained by the Agency
for Healthcare Research and Quality (AHRQ), is a 20%
stratified representative sample of all US inpatient stays in
acute-care non-federally funded institutions. It contains
records on approximately 8 million hospitalizations each
year from over 1000 US facilities.
Core hospital stay files contain details on patient demo-
graphics (e.g., age, sex, race), International Classification of
Diseases, 9th Revision, Clinical Modification (ICD-9-CM)
diagnosis codes (15–25, depending on the year), Elixhauser
comorbidities [16], length of hospital stay, discharge
status, and total charges. Each hospitalization is assigned
a specific sample weight used to estimate national rates.
Hospital characteristics, such as geographic location, teach-
ing status, number of beds, and hospital-specific cost-to-
charge ratios are provided in separate files and can be
linked to the hospitalization records.
The HCUP-NIS data used in this study represent de-
identified human subject data. The database does not
contain data elements that would allow direct or indirect
identification of specific individuals. All parties with ac-
cess to the data were signatories of HCUP’s formal data
use agreement (DUA), including the provision that no
cell sizes less than 10 can be reported, and additionally
completed the HCUP DUA Training. This provision is
deemed by AHRQ to be an adequate safeguard against
identification of individual patients.
Sample selection
Hospitalizations of patients considered to be at risk for
mucormycosis were identified based on the following
hierarchy of high-risk categories for this infection:
A. Severely immunocompromised (leukemia/lymphoma,
hematopoietic stem cell or bone marrow transplant,
chemotherapy, other immune disorders, solid organ
transplant, long-term steroid use)
B. Critically ill (trauma, septicemia, bacteremia,
necrotizing fasciitis, intracranial hemorrhage,
mechanical ventilation for over 96 hours)
C. Mildly/moderately immunocompromised (end-stage
renal disease/hemodialysis, lupus, malignant solid
tumors, diabetic ketoacidosis, blood disorders,
diabetes)
D. Major surgery or pneumonia
Categories were identified based on ICD-9-CM diag-
nosis and procedure codes, as well as diagnosis-related
group (DRG) codes listed for the admission. Codes by
date or time within the hospitalization are not available
in the NIS database. Hospitalizations not falling into one
of these categories were excluded from the analysis. Be-
cause the assignment to a risk group was hierarchical
(that is, a hospitalization was only assigned to a lower
risk group if it did not meet the criteria for the group
above it in the hierarchy), the four groups were mutually
exclusive. The categories were developed based on both
the distribution of the observed comorbid conditions
among all mucormycosis hospitalizations in a prelimin-
ary analysis and on the clinical understanding of trad-
itional high risk factors (categories A and C).
All four categories together comprised the analysis pool
for hospitalizations at risk for mucormycosis. Among
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these high-risk groups, hospitalizations with mucormyco-
sis were identified by the ICD-9-CM diagnosis code 117.7
(Zygomycosis [Phycomycosis or Mucormycosis]; cases)
and matched to high-risk hospitalizations without a
mucormycosis diagnosis (non-cases) based on a propen-
sity score (PS). Since the NIS is strictly an administrative
database without any clinical data, we were unable to clas-
sify mucormycosis cases further as “proven”, “probable,” or
“possible” as recommended by the European Organization
for Research and Treatment of Cancer/Invasive Fungal
Infections Cooperative Group and the National Institute
of Allergy and Infectious Diseases Mycoses Study Group
(EORTC/MSG). To minimize center effect, selection of
non-cases was restricted to hospitals with at least one
mucormycosis hospitalization in the same year.
Study measures
Patient and hospital characteristics were evaluated for
all hospitalizations. We included demographic (age at
admission, sex, race, median household income, payer
type, and year of admission), clinical (high-risk category,
Elixhauser comorbidities [16], number of listed discharge
diagnoses, receipt of abdominal procedure/surgery, and
total number of listed procedures), hospital (geographic
region, urbanicity, teaching status, and size [number of
beds]), and admission-specific (source [e.g., emergency room,
another hospital, etc.], and urgency [e.g., emergency, ur-
gent, elective]) characteristics.
We examined the following outcomes: in-hospital mor-
tality, discharge destination for survivors (e.g., short-term
hospital, skilled nursing facility, intermediate care facility,
home health care, etc.), length of stay (LOS), and total
hospitalization charges and costs. Costs were derived
by applying hospital-specific cost-to-charge ratios pro-
vided by HCUP to the charges for each individual
hospitalization. All costs and charges were adjusted to
2011 USD using the medical care component of the US
Consumer Price Index. Indirect (non-medical) costs were
not available in the database and thus excluded from ana-
lyses. The NIS data do not allow for the calculation of at-
tributable costs.
Data analyses
Propensity scores were computed by modeling the likeli-
hood of having mucormycosis using a logistic regres-
sion. Predictors included patient (age, sex, race, median
household income, payer, number of comorbidities, and
high-risk group), hospital (geographic region, urbanicity,
teaching status, size), and admission (weekend/weekday
admission, presence of abdominal procedure/surgery, and
year of admission) characteristics. Predictors were chosen
on the basis of an expected or potential relationship
to mucormycosis exposure. Data availability was also a
factor in selecting predictors. Variables that were not
consistently available across years or hospitals were not in-
cluded to minimize the number of hospitalizations that
would need to be excluded.
Non-mucormycosis high-risk hospitalizations from hos-
pitals with at least one mucormycosis hospitalization were
matched 3:1 to mucormycosis patients using a greedy
8-to-1 digit matching algorithm [17]. Stratified ana-
lyses by the high-risk group were conducted for length of
stay, inpatient mortality, and total hospitalization charges
and costs.
All study measures were compared between cases and
non-cases before and after matching. Mean, standard de-
viation, median, interquartile range (IQR), minimum and
maximum were reported for continuous measures, and
proportions were reported for categorical variables. Sig-
nificance was tested for proportions using the Rao-Scott
Chi-Square Test, and for continuous measures using an
independent sample t-test. An alpha level of 0.05 was
used to assess statistical significance.
Results
Patient characteristics
Among the total of over 300 million hospitalizations in
the US during the study period, 146,300,612 had at least
one of the high-risk conditions, of whom 5,515 carried a
diagnosis of mucormycosis (< 0.01%, Figure 1). These
5,515 cases represented 94.0% of all hospitalizations that
carried a diagnosis of mucormycosis; the remaining 6.0%
failed to meet the criteria for a high-risk condition.
Cases differed from non-cases in the unadjusted com-
parison along most characteristics, including sex, age,
race, high-risk group, and number of procedures (Table 1).
After propensity score matching 5,346 (96.9%) cases to
15,999 non-cases, many of these differences disappeared.
Unless stated otherwise, all the results below represent the
post-match data. The mean age for both cases and non-
cases was 50 years with the plurality falling into the age
group between 45–64 years (43.5% and 43.7% for cases
and non-cases, respectively). There were slightly more
males than females in both groups (59.5% and 59.0% of
cases and non-cases, respectively), and the majority
were of White race (53.3% and 55.9%), followed by His-
panic (13.6% and 13.3%) and African American (10.7%
and 10.0%). All hospitalizations were evenly distributed
across the four median household income quartiles.
Private payers were most common in both cases and
non-cases (38-40%), followed by Medicare (31-34%)
and Medicaid (21%).
One-half of the hospitalizations among both cases and
non-cases were considered severely immunocompromised
(high-risk group A), and one-fifth of cases and non-cases
fell into the critically ill (high-risk group B) category.
Approximately one quarter of both cases and non-cases
were in high-risk groups B and D (major surgery and
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pneumonia), those considered non-traditional risk factors
for mucormycosis. The most common comorbid conditions
for cases and non-cases after matching included: hyperten-
sion (36.8% and 44.6%, respectively), fluid and electrolyte
disorders (42.5% and 27.5%), and diabetes with complica-
tions (26.9% and 22.3%).
Hospital and hospital admission characteristics
Approximately one third of matched hospitalizations
were from hospitals in the West and South census re-
gions. Three-quarters of these institutions were teaching
hospitals and a slightly higher proportion were large (≥
100 beds; 76.6% among cases and 79.5% among non-
cases). Cases had a higher risk than non-cases of being
admitted urgently (26.0% versus 18.2% for non-cases).
Hospitalization outcomes
Hospitalization outcomes are presented in Tables 2 and 3.
Differences in the outcomes between cases and non-cases
were larger before matching, but remained substantial
and statistically significant after matching. Length of
stay was significantly greater among matched cases
(mean: 24.5 days; median: 14.0 days) than non-cases
(8.0 days; 4.0 days), equating to 16.5 mean excess days
of hospitalization among cases (standard error [SE] = 2.2;
P < 0.001). Inpatient mortality was over five times higher
among cases (22.1%) than among matched non-cases
(4.4%, mean difference 17.7% [SE 1.3%; P < 0.001]). Aver-
age total costs varied considerably, with $90,272 (me-
dian $51,004) observed among cases and $25,746
(median $12,327) among non-cases. This difference
represents $64,526 in mean excess costs for mucormyco-
sis cases (SE = $7,805; P < 0.001). Differences between
cases and non-cases for all three outcomes persisted over
the 8-year timespan of the study, with no clear trend in
the magnitude of the difference over time. For example,
in-hospital mortality for mucormycosis cases was 25.2% in
2003 and 25.7% in 2009.
Critically ill patients (high-risk group B) demonstrated
the largest differences in the outcomes between matched
cases and non-cases (excess mortality: 25.7%; mean ex-
cess LOS: 24.7 days, [median difference: 19 days]); mean
excess costs: $101,388, [median difference: $69,618]),
followed by the severely immunocompromised patients
Figure 1 Sample selection flow chart.
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Table 1 Patient and hospital characteristics
Before propensity-score matching1 After propensity-score matching1
Characteristic Cases Non-Cases P- value3 Cases Non-Cases P- value3
N (unweighted) 1,120 29,759,178 1,084 3,252
N (weighted) 5,515 146,295,097 5,346 15,999
Sex (%) < 0.001 0.7550
Female 39.6% 53.2% 40.5% 41.0%
Male 60.4% 46.6% 59.5% 59.0%
Unknown 0.0% 0.3% - -
Age (%)
Mean (SD) 49.5 (20.0) 59.7 (21.4) < 0.001 49.6 (19.9) 49.7 (19.9) 0.9074
< 44 33.1% 21.4% 33.0% 32.6%
45 to 64 43.6% 31.0% 43.5% 43.7%
≥ 65 23.4% 47.6% 23.5% 23.7%
Race (%) < 0.001 0.8093
White 53.6% 54.9% 53.3% 55.9%
African-American 10.5% 10.7% 10.7% 10.0%
Hispanic 13.5% 7.8% 13.6% 13.3%
Other/Unknown 22.4% 26.5% 22.4% 20.8%
Primary expected payer (%) < 0.001 0.7473
Medicare 33.7% 51.1% 33.6% 31.2%
Medicaid 21.0% 11.2% 20.8% 20.8%
Private 37.4% 29.4% 37.8% 39.9%
Other/Unknown 8.0% 8.3% 7.8% 8.1%
High-risk conditions2 (%) < 0.001 0.5281
(A) Severely immunocompromised 49.7% 6.2% 49.1% 49.0%
(C) Mildly/moderately immunocompromised 25.1% 45.5% 25.5% 23.8%
(B) Critically ill 20.0% 20.3% 20.0% 21.8%
(D) Major surgery or Pneumonia 5.3% 27.9% 5.5% 5.4%
Number of Elixhauser comorbidities
Mean (SD) 2.7 (1.8) 2.4 (1.8) < 0.001 2.7 (1.8) 2.6 (1.7) 0.0340
Median (IQR) 2 (1–4) 2 (1–3) 3 (1–4) 2 (1–4)
Number of listed diagnoses
Mean (SD) 12.1 (4.8) 8.3 (4.3) < 0.001 12.2 (4.8) 9.2 (4.6) <0.001
Median (IQR) 11 (9–15) 8 (5–10) 11 (9–15) 9 (6–12)
Number of listed procedures
Mean (SD) 5.3 (4.5) 2 (2.3) < 0.001 5.3 (4.5) 2.5 (2.8) <0.001
Median (IQR) 5 (2–8) 1 (0–3) 5 (2–8) 2 (1–3)
Abdominal procedures or surgeries4 (%) 5.5% 12.0% < 0.001 5.4% 4.9% 0.5314
Geographic Region (%) < 0.001 0.2629
Northeast 15.4% 19.5% 15.4% 16.7%
Midwest 18.5% 23.6% 18.5% 16.1%
West 31.9% 18.2% 32.4% 33.3%
South 34.2% 38.7% 33.6% 33.9%
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(high-risk group A; 19.7%; 17.4 days [10 days]; $70,064
[$43,038]). Patients considered only mildly or moder-
ately immunocompromised (high-risk group C) or those
with major surgery or pneumonia (high-risk group D)
exhibited smaller differences in these outcomes (C: 7.9%,
8.7 days [4 days], $32,530 [$15,452]; D: 19.5%, 16.9 days
[13 days], $48,181 [$31,489]).
Discussion
We confirm that mucormycosis remains a rare infection,
present in less than 0.01% of all US hospitalizations be-
tween 2003 and 2010. Some degree of immune com-
promise, identified in three-quarters of admissions with
this diagnosis, continues to represent the most common
risk factor for this infection. The remainder, however,
carried coexisting conditions less traditionally recog-
nized as associated with mucormycosis, such as critical
illness, pneumonia, and major surgery. Of the admissions
over the eight years examined carrying a mucormycosis
ICD-9-CM code, only 6% failed to fall into one of the four
high-risk groups. Propensity-score matched analysis re-
vealed a dramatic rise in hospital mortality (mean excess
17.7% [SE 1.3%]), LOS prolongation (mean excess days
16.5 [SE 2.2]) and costs (mean excess costs $64,526 [SE
$7,805]) associated with a diagnosis mucormycosis.
Prior studies examining outcomes among patients with
mucormycosis have been limited by small numbers of pa-
tients with mucormycosis examined as a subset of those
with IFIs. For example, a recent single center study by
Dodds and colleagues [13] compared 200 patients with an
IFI diagnosis (including 4 mucormycosis cases and also
cases of aspergillosis, cryptococcosis, and invasive candid-
iasis) to 200 matched controls without IFIs. In this study,
IFI diagnosis imparted a mean excess of 7.4 days in hos-
pital LOS along with approximately $37,000 (2011 USD)
in excess cost.
Menzin and colleagues [15] examined the economic
burden of IFIs using a single year (2004) of the HCUP –
NIS. In this matched cohort study of nearly 12,000 IFI
hospitalizations, only 119 had a mucormycosis ICD-9-
CM code. Those with mucormycosis suffered a 12%
higher absolute risk of hospital mortality and a 10.7-day
excess in the hospital LOS, corresponding to approxi-
mately $41,000 (2011 USD) in excess costs. Our study
adds power and precision to these results, given our
focus specifically on mucormycosis and the large num-
ber of cases. Data from this study generally confirm the
findings from both of these earlier reports [13,15]. Com-
pared to the analysis by Dodds, our finding of an excess
mean LOS of 16.5 days and costs of $64,526 emphasizes
the disproportionate financial impact of mucormycosis.
Our findings also add to and build on those of Menzin
et al., in that our results not only draw on the more recent
data from HCUP-NIS and on a much larger cohort of pa-
tients with mucormycosis, but reflect the efforts of a more
rigorous matching algorithm. This helps to assure greater
Table 1 Patient and hospital characteristics (Continued)
Hospital location (%) < 0.001 0.6274
Urban 95.9% 86.9% 96.8% 97.0%
Rural 3.1% 12.7% 3.2% 3.0%
Missing 1.0% 0.5% - -
Hospital teaching status (%) < 0.001 0.4091
Teaching 72.6% 46.8% 73.1% 74.3%
Non-teaching 26.4% 52.8% 26.9% 25.7%
Missing 1.0% 0.5% - -
Hospital bed size (%) < 0.001 0.0668
Small (1–49 beds) 7.7% 12.2% 7.8% 6.6%
Medium (50–99 beds) 15.2% 23.7% 15.5% 13.9%
Large (≥ 100 beds) 76.1% 63.6% 76.6% 79.5%
Missing 1.0% 0.5% - -
Source: HCUP 2003–2010.
[1] Non-mucormycosis hospitalizations from hospitals with at least one mucormycosis patient were matched 3:1 to mucormycosis hospitalizations using a greedy
8 to 1 digit matching algorithm. This algorithm first matches on 8 digits of propensity score and then subsequently on 7 and so on.
[2] All high-risk groups were mutually exclusive; ordered here by prevalence post-matching. Severely immunocompromised (A) conditions include leukemia/
lymphoma/HSCT/BMT, chemotherapy, other immune disorders, solid organ transplant or long-term steroid use. Critically ill (B) conditions include trauma, septicemia,
bacteremia, necrotizing fasciitis, intracranial hemorrhage and mechanical ventilation for 96+ hours. Mildly/moderately immunocompromised (C) conditions include
ESRD/hemodialysis, lupus, malignant solid tumors, diabetic ketoacidosis, blood disorders, and diabetes. Major surgery or pneumonia (D) includes selected thoracic,
cardiac, vascular, abdominal, peripheral, urology, and neurology surgeries, other major procedures, and pneumonia.
[3] Significance was tested for proportions using the Rao-Scott Chi-Square Test. Continuous measures were tested using an independent sample t-test.
[4] Abdominal procedures/surgeries include: ICD-9-CM 43.XX-50.XX, 51.2X, and 52.XX-54.XX, excluding 43.1X, 43.4X, 43.9X, 44.1X, 44.22, 44.43, 44.44, 44.49, 44.91,
45.1X-45.3X, 46.32, 46.32, 46.39, 48.2X, 48.3X, 50.1X, 50.9X, 52.0X, 52.1X, 52.4X, 52.9X, 54.22-54.29, 54.9X.
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Table 2 Hospitalization outcomes before and after propensity-score matching
Before propensity-score matching1 After propensity-score matching1
Characteristic Cases Non-Cases p value2 Mean SE Cases Non-Cases p value2 Mean SE
N (unweighted) 1,120 29,759,178 1,084 3,252
N (weighted) 5,515 146,295,097 5,346 15,999
Length of stay (days)
Mean (SD) 24.5 (32.0) 5.8 (8.3) < 0.001 18.6 0.4 24.5 (31.9) 8.0 (11.9) < 0.001 16.5 0.4
Median (IQR) 14 (6–30) 4 (2–7) 14 (6–30) 4 (2–9)
Mortality (%) 22.2% 3.6% < 0.001 18.7% 0.6% 22.1% 4.4% < 0.001 17.7% 0.6%
Discharge type among survivors (%) < 0.001 < 0.001
Routine 46.0% 63.3% 46.0% 69.9%
Short-term hospital 9.6% 2.5% 9.7% 1.8%
Other transfers3 18.5% 19.3% 18.8% 12.3%
Home health care 24.8% 14.0% 24.3% 14.8%
Other/unknown 1.1% 0.9% 1.2% 1.1%
Total Charges
Mean (SD) $237,090 ($283,375) $44,442 ($69,052) < 0.001 $192,648 $3,816 $237,114 ($285,769) $71,698 ($114,452) < 0.001 $165,417 $4,012
Median (IQR) $128,682 $25,423 $127,171 $33,958
($48,025 - $303,348) ($13,423 - $48,779) ($47,653-$301,540) ($17,241 -$74,044)
Total Costs
Mean (SD) $90,107 ($111,760) $16,582 ($24,509) < 0.001 $73,525 $1,505 $90,272 ($112,964) $25,746 ($41,207) < 0.001 $64,526 $1,579
Median (IQR) $51,170 $9,943 $51,004 $12,327
($17,869 - $112,910) ($5,518 - $18,392) ($17,256 -$112,928) ($6,531 - $27,424)
Source: HCUP 2003–2010.
[1] Non-mucormycosis hospitalizations from hospitals with at least one mucormycosis patient are matched 3:1 to mucormycosis hospitalizations using a greedy 8 to 1 digit matching algorithm.
[2] Significance was tested for proportions using the Rao-Scott Chi-Square Test. Continuous measures were tested using an independent sample t-test.
[3] Includes skilled nursing facility, intermediate care, and any other type of facility.



















internal validity. Moreover, specific to mucormycosis, our
clinical and economic results are highly generalizable within
the US as they are derived from a representative sample of
US acute care institutions.
Although generalizable and internally valid, our study
needs to be interpreted with some caution. One concern
stems from the similarity of our mortality data to that ob-
served in a specific population of patients with mucormy-
cosis. Hammond and colleagues [1] studied 30 adult
hematopoietic stem cell transplant or hematologic malig-
nancy patients with mucormycosis and reported a 6-week
mortality rate of 20%. Our aggregate mortality rate was
similar to what is reported by Hammond and colleagues.
However, our stratified mortality data add further granu-
larity by untangling the heterogeneity in this outcome as a
function of the specific risk factors for mucormycosis. In-
deed, the mortality rate among those with severe immune
compromise in our study mirrors that in the analysis by
Hammond et al. In contrast, we found hospital mortality
among those with mild immune compromise to be sub-
stantially lower than among the severely immunocom-
promised. At the same time, among those who were
critically ill mortality was even higher than among those
with severe immune compromise.









N (weighted) 2,623 1,067 1,364 292
Length of stay (days)
Mean (SD) 25.6 (34.0) 35.6 (37.9) 14 (15.7) 22.5 (30.59)
Median (IQR) 15 (6–32) 25 (10–45) 8 (4–20) 16 (8–24)
Mortality (%) 23.4% 35.3% 9.4% 21.3%
Total Charges




















N (weighted) 7,839 3,488 3,804 867
Length of stay (days)
Mean (SD) 8.2 (10.67) 10.9 (17.9) 5.3 (6.12) 5.6 (7.8)
Median (IQR) 5 (3–9) 6 (3–13) 4 (2–6) 3 (2–6)
Mortality (%) 3.7% 9.6% 1.5% 1.7%
Total Charges




















[1] All high-risk groups were mutually exclusive. Severely immunocompromised (A) conditions include leukemia/lymphoma/HSCT/BMT, chemotherapy, other
immune disorders, solid organ transplant or long-term steroid use. Critically ill (B) conditions include trauma, septicemia, bacteremia, necrotizing fasciitis, intracranial
hemorrhage and mechanical ventilation for 96+ hours. Mildly/moderately immunocompromised (C) conditions include ESRD/hemodialysis, lupus, malignant solid
tumors, diabetic ketoacidosis, blood disorders, and diabetes. Major surgery or pneumonia (D) includes selected thoracic, cardiac, vascular, abdominal, peripheral, urology,
and neurology surgeries, other major procedures, and pneumonia.
Note: Charges and costs reported in 2011 USD.
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Our study is subject to a number of additional limita-
tions. First, it was cross-sectional, and thus did not allow
us to explore hospital events in relation to the onset of
mucormycosis. For this reason it is likely that at least
some of the excess days and costs seen in mucormycosis
group were incurred prior to the onset of mucormycosis.
Therefore, we were unable to assess the degree to which
this burden was specifically attributable to mucormycosis.
The cross-sectional nature of the analysis (and database)
also precluded the ability to factor the timing of concomi-
tant diagnoses within the admission into the high-risk
categorization process. Due to variability in data availabil-
ity across years, not all hospitalization characteristics were
included as predictors in the logistic regression to estimate
propensity scores. Specifically, admission source (approxi-
mately 30% missing) and admission type (approximately
20% missing) were excluded.
Furthermore, we relied on diagnosis codes to identify
cases of mucormycosis. This predisposes our case identi-
fication to potential misclassification, including inadvertent
exclusion of “probable” and “possible”mucormycosis cases.
However, if this misclassification is non-differential, then
the magnitude of group differences found in our study is
actually likely to be biased toward the null. In other words,
if such non-differential misclassification exists, then the ac-
tual between-group differences in the outcomes are poten-
tially even greater than what we computed. Lack of clinical
data also limited our ability to adjust for confounding clin-
ical characteristics when assessing excess costs, such as
the site of the mucormycosis infection. In addition, the
cost analysis did not include costs of physician services,
patient out-of-pocket expenses, indirect costs, costs post-
discharge, or costs in the outpatient setting; therefore, this
study may have underestimated the true burden of mucor-
mycosis from a societal perspective.
Conclusions
In summary, mucormycosis remains a rare but deadly in-
fection among hospitalized patients. In addition to its clin-
ical burden, it is associated with a vast increase in hospital
resource use as measured by both LOS and costs. Finally,
approximately one quarter of all admissions afflicted with
mucormycosis have non-traditional risk factors for this in-
fection such as critical illness, pneumonia, and major sur-
gery. Although rare, by virtue of its dismal outcomes,
mucormycosis demands more concentrated attention from
the research and clinical communities.
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